Meningitis causes inflammation of the meninges which is the protective membranes surrounding the in the brain and spinal cord. The inflammation is caused by an infection in the fluid surrounding the brain or spinal. Meningococcal Meningitis is caused by Neisseria meningitidis, also called meningococcus, which enters the bloodstream. Meningococcal Meningitis has 13 serogroups including serogroup A. Meningococcal Meningitis Serogroup A is very common in Sub-Saharan Africa and Asia, but there is a vaccine that targets this specific type. The symptoms of Meningococcal Meningitis Serogroup A are headache, fever, and stiff neck and it is treated with antibiotics.
Meningococcal Meningitis, Serogroup A Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Meningococcal Meningitis, Serogroup A below!
For more information on how to use Laverne, please read the How to Guide.
We have 265 products for the study of Meningococcal Meningitis, Serogroup A that can be applied to Western Blot, Immunocytochemistry/Immunofluorescence, Flow Cytometry, Immunohistochemistry from our catalog of antibodies and ELISA kits.
Meningococcal Meningitis, Serogroup A is also known as Serogroup A Meningococcal Meningitis.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.